Drugs / CCCR-NK92 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03656705 | Sep 2018 → Nov 2020 | non-small cell lung carcinoma | Henan Medical University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCCR-NK92 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03656705 ↗ |
| Modality | Cell therapy | “CCCR-NK92 cells immunotherapy” NCT03656705 ↗ |
| Route | Intravenous | “CCCR-NK92 cells will be administered intravenously over 1h.” NCT03656705 ↗ |